Children treated with mepolizumab during asthma flare-ups showed a significant reduction in eosinophil-driven type 2 (T2) ...

A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease ...

STRENGTHS AND LIMITATIONS OF THIS STUDY Randomised head-to-head study of mepolizumab versus omalizumab in children and young people (CYP) with severe therapy resistant asthma (STRA) and refractory ...

Time to first moderate or severe exacerbation longer with mepolizumab in patients with COPD, history of exacerbations, eosinophil count greater than or equal to 300 cells/µL ...

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 versus 1.01 events per year; rate ratio, 0.79 ...

Although both benralizumab and mepolizumab were associated with a decline in eosinophil counts, a deeper, more significant reduction was observed in the benralizumab treatment arm at all 3 time ...

In such cases, mepolizumab might be a more suitable option. Furthermore, mepolizumab is FDA-approved for treating EGPA (62). When added to standard treatment, benralizumab reduced the nasal polyp ...